Stocktoria
CapsoVision, Inc CV
CapsoVision, Inc (CV) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $13.6M at a -186.8% net margin.
Beneish M-score: -3.26 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CV | CapsoVision, Inc | 2/9 | — | — | +15.3% |
| HYPR | Hyperfine, Inc. | 4/9 | -16.31 | — | +5.2% |
| NUWE | Nuwellis, Inc. | 2/9 | — | — | — |
| QTI | QT IMAGING HOLDINGS, INC. | 5/9 | -4.34 | — | — |
| POCI | PRECISION OPTICS CORPORATION, INC. | 3/9 | -8.27 | — | -0.1% |
| NRXS | Neuraxis, INC | 3/9 | — | — | — |
| HCIL | Hongchang International Co., Ltd | 2/9 | 2.23 | — | — |
About CapsoVision, Inc
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
FAQ
Is CV financially healthy?
CapsoVision, Inc's Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does CV pay a dividend?
No, CapsoVision, Inc does not currently pay a dividend.
How profitable is CV?
In FY2025, CapsoVision, Inc had a net margin of -186.8% and a return on equity of -190.9%.
What is the analyst price target for CV?
The average Wall-Street price target for CapsoVision, Inc is $10.00, about 45.8% above the recent price, from 1 analysts.
Is CV a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on CapsoVision, Inc: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.